Channels
All News
In Focus
Special
AI
Bioregnum
Biotech Voices
Cell/Gene Tx
China
Coronavirus
Deals
Diagnostics
Discovery
FDA+
Financing
Health Tech
Law
Letters to the Editor
Manufacturing
Marketing
Nikkei Biotechnology
Opinion
Outsourcing
Peer Review
People
Pharma
R&D
Startups
Weekly
Webinars
Biopharma Jobs
More
Work at Endpoints
Letter to Editors
Editorial Standards
IPO Tracker
Webinars
Events
Sponsored Posts
Advertise
Privacy Policy
Endpoints Merch
About Us
Help
SIGN UP
LOG IN
Deals channel feed
Fresh off positive Nuplazid data, Acadia adds new clinical drug from Vanderbilt in milestone-heavy deal
6 years ago
Amid lab space scarcity, a life sciences complex to rise in South San Francisco hub
6 years ago
R&D
'Deeply committed' Jim Wilson pours more of his life's work into Passage Bio — locking in more gene therapy programs, new tech
6 years ago
Cell/Gene Tx
Stepping on BioMarin's turf, PTC Therapeutics picks up PKU drug for a song
6 years ago
Tetraphase has two suitors, despite struggling market for antibiotics
6 years ago
Boehringer Ingelheim adds second AI partner in a month
6 years ago
AI
AbbVie gets the FTC's divided blessing for its $63B Allergan buyout — freeing Brent Saunders to blaze a new path
6 years ago
People
Dealmaking spiked to record levels in April as Covid-19 triggered a fever of partnering. But what happens to collaborations in a new world seen through Zoom?
6 years ago
Alexion bags a discount biotech buyout for $1.4B, branching out in new directions from its Soliris franchise
6 years ago
BioMarin broadens its gene therapy horizons with a new R&D alliance in rare cardio cases
6 years ago
R&D
Cell/Gene Tx
Menarini bags Stemline and a rare disease drug in $677M buyout. But will a better offer follow?
6 years ago
Amid Covid-19 hunt, Pfizer adds Lyme disease vaccine in $308M deal with Valneva
6 years ago
AstraZeneca vaults to the front of the Covid-19 vaccine race, teaming up to globalize Oxford candidate
6 years ago
Coronavirus
Having sold its corporate self, Tocagen auctions off scientific platform to San Diego biotech
6 years ago
Cell/Gene Tx
Takeda auctions off a $670M portfolio of drugs and manufacturing ops, getting closer to its $10B goal
6 years ago
Pharma
Amid remdesivir craze Gilead finds time for another oncology pact — looping in all things NK cells
6 years ago
Astellas snaps up mitochondria-focused biotech, beefs up drug discovery in budget deal
6 years ago
Esperion strikes Japan deal for 'goldilocks' cholesterol drug, bags $60M cash as pandemic forces virtual US rollout
6 years ago
Novartis eyes a new market with its buyout of a small digital therapeutics player
6 years ago
BARDA bets $483M on Moderna’s Covid-19 vaccine as the biotech plots ultra-fast PhIII, recruiting 150 staffers to scale up 24/7
6 years ago
Coronavirus
Is Gilead chief Dan O’Day ready for a new biotech deal in the oncology field?
6 years ago
Molecule-in-21-days AI startup Insilico adds Boehringer to list of Big Pharma partners
6 years ago
AI
LEO Pharma mounts another challenge to the eczema giants, betting $40M cash on a drug from China
6 years ago
One of the best connected biotech startups in Boston snags a plum discovery deal with Novartis
6 years ago
First page
Previous page
91
92
93
94
95
96
97
Next page
Last page